### NCCN Guidelines Panel Members

#### Penile Cancer

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter E. Clark, MD</td>
<td>Chair, Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td>Philippe E. Spiess, MD, MS</td>
<td>Vice chair, Moffitt Cancer Center</td>
</tr>
<tr>
<td>Neeraj Agarwal, MD</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>Matthew C. Biagioli, MD, MS</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Mario A. Eisenberger, MD</td>
<td>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td>Richard E. Greenberg, MD</td>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td>Harry W. Herr, MD</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td>*Brant A. Inman, MD, MSc</td>
<td>Duke Cancer Institute</td>
</tr>
<tr>
<td>A. Karim Kader, MD, PhD</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Deborah A. Kuban, MD</td>
<td>The University of Texas</td>
</tr>
<tr>
<td>MD Anderson Cancer Center</td>
<td></td>
</tr>
<tr>
<td>Timothy M. Kuzel, MD</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>Subodh M. Lele, MD</td>
<td>Fred &amp; Pamela Buffett Cancer Center at The Nebraska Medical Center</td>
</tr>
<tr>
<td>Jeff Michalski, MD, MBA</td>
<td>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</td>
</tr>
<tr>
<td>Jeffrey S. Montgomery, MD, MHSA</td>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Lance C. Pagliaro, MD</td>
<td>The University of Texas</td>
</tr>
<tr>
<td>Sumanta K. Pal, MD</td>
<td>City of Hope Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Anthony Patterson, MD</td>
<td>St. Jude Children’s Research Hospital/University of Tennessee Health Science Center</td>
</tr>
<tr>
<td>Elizabeth R. Plimack, MD, MS</td>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td>Kamal S. Pohar, MD</td>
<td>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</td>
</tr>
<tr>
<td>Michael P. Porter, MD, MS</td>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
<tr>
<td>Jerome P. Richie, MD</td>
<td>Dana-Farber/Brigham and Women’s Cancer Center</td>
</tr>
<tr>
<td>Wade J. Sexton, MD</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>William U. Shipley, MD</td>
<td>Massachusetts General Hospital Cancer Center</td>
</tr>
<tr>
<td>Eric J. Small, MD</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Donald L. Trump, MD</td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td>Jonathan Tward, MD</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>Geoffrey Wile, MD</td>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td>Timothy G. Wilson, MD</td>
<td>City of Hope Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Philip E. Spiess, MD</td>
<td>° Urology</td>
</tr>
<tr>
<td>Richard E. Greenberg, MD</td>
<td>† Medical oncology</td>
</tr>
<tr>
<td>Mario A. Eisenberger, MD</td>
<td>‡ Hematology/Hematology oncology</td>
</tr>
<tr>
<td>Richard E. Greenberg, MD</td>
<td>§ Radiotherapy/Radiation oncology</td>
</tr>
<tr>
<td>Michael P. Porter, MD, MS</td>
<td>° Pathology</td>
</tr>
<tr>
<td>* Writing committee member</td>
<td>* Writing committee member</td>
</tr>
</tbody>
</table>

### NCCN Guidelines Panel Disclosures

* Version 1.2014, 10/08/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2013.
Summary of the changes in the 1.2014 version of the Guidelines for Penile Cancer from the 1.2013 version include:

### PN-1
- **Primary evaluation**
  - Imaging by MRI or ultrasound and corresponding footnote “MRI or ultrasound are optional studies based on clinical suspicion and to further define concerning physical exam findings” were removed.
  - Pathologic diagnosis heading was changed to “Clinical Diagnosis.”

### PN-2
- **T2 or greater**
  - The primary treatment for T2 tumors only was revised from “Radiotherapy ± concurrent chemotherapy (category 2B)” to “Radiotherapy (category 2B) or Radiotherapy with concurrent chemotherapy (category 3).”

### PN-3
- **Low risk, “T1G1” was clarified as “T1a”**
- **Intermediate risk** was combined with “High risk”
  - Intermediate risk, “T1G2” was clarified as “T1b”
  - High risk, “G4” was added.

### PN-4
- **Unilateral lymph node <4 cm was separated into “Low-risk primary lesion” and “High-risk primary lesion.”**
  - For a low-risk primary lesion, an FNA is recommended. If negative, “surveillance” was added as an option with excisional biopsy.
  - For high-risk primary lesion, the treatment recommendation is ILND.
  - Footnotes were removed and applied within the algorithm:
    - For a high-risk primary lesion, it is recommended to proceed directly to ILND and not FNA.
    - Surveillance can be considered in patients with a negative FNA provided they are carefully surveyed. See Surveillance (PN-6).
    - Footnote “o” was added: “High-risk primary lesion: T1, high-grade, LVI, >50% poorly undifferentiated.”

### PN-5
- **Management of Bulky/Unresectable Inguinal Lymph Nodes” page was extensively revised.**
  - Footnote “q” was added: “For viable disease post-chemotherapy, consider PLND.”

### Principles of Surgery

### PN-A
- 1st bullet was modified by clarifying that laser therapy and glansectomy are category 2B recommendations.
- 3rd bullet, 2nd sub-bullet was revised by adding “≥” to “pT1G3.”
- Footnotes “1” was added: “See Discussion for further details regarding ILND and PLND.”

### Principles of Radiotherapy

### PN-B
- For T1-2, N0, if tumor <4 cm:
  - 1st sub-bullet, “preferred approach” was added to “Brachytherapy alone.”
  - 2nd sub-bullet was modified by adding: “EBRT with or without chemotherapy: Total dose 65-70 Gy with conventional fractionation using appropriate bolus to primary penile lesion with 2 cm margins” and removing the statement “Consider prophylactic inguinal lymph node irradiation.”
- For T3-4 or N+, “surgically unresectable” was added for clarification.
- Footnotes 1 through 3 were added.

### Principles of Chemotherapy

### PN-C 1 of 2
- Second-line therapy, 2nd bullet:
  - “irinotecan” was removed.
  - “Strongly consider a clinical trial” was added.

### PN-C 2 of 2
- Radiosensitizing agents and combinations (For radiotherapy with concurrent chemotherapy) was separated into “preferred” and “alternate options.”
  - **Preferred**
    - Cisplatin alone, or in combination with 5-FU
  - **Alternate options**
    - Mitomycin C in combination with 5-FU
    - Capecitabine

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**NCCN Guidelines Version 1.2014**

**Penile Cancer**

### PRIMARY EVALUATION

**Suspicious penile lesion**

- **H&P**
  - Risk factors
    - balanitis, chronic inflammation, penile trauma, lack of neonatal circumcision, tobacco use, lichen sclerosus, poor hygiene, sexually transmitted disease
  - Lesion characteristics
    - diameter
    - location
    - number of lesions
    - morphology (papillary, nodular, ulcerous, or flat)
    - relationship to other structures (submucosal, corpora spongiosa, and/or cavernosa, urethra)

- **Cytology or histologic diagnosis**
  - Punch, excisional, or incisional biopsy

### CLINICAL DIAGNOSIS

- Tis or Ta
- T1
- Grade 1-2
- Grade 3-4
- T2 or greater

### PRIMARY TREATMENT

- **Topical therapy**
- **Wide local excision including circumcision**
- **Laser therapy (category 2B)**
- **Complete glansectomy (category 2B)**

If recurrent disease, **see PN-7** or if metastatic disease, **see PN-8**

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*a*Topical therapy may include topical imiquimod (5%) or 5-fluorouracil (5-FU) cream.
### Pathologic Diagnosis

#### Grade 1-2
- **T1**
- **Grade 3-4**

#### T2 or greater

<table>
<thead>
<tr>
<th>PRIMARY TREATMENT&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wide local excision;&lt;sup&gt;c,d&lt;/sup&gt; possible STSG or FTSG or Laser therapy (category 2B) or Radiotherapy&lt;sup&gt;e&lt;/sup&gt; (category 2B)</td>
</tr>
<tr>
<td>T2 tumors only: Radiotherapy&lt;sup&gt;e&lt;/sup&gt; (category 2B) or Radiotherapy&lt;sup&gt;e&lt;/sup&gt; with concurrent chemotherapy&lt;sup&gt;i&lt;/sup&gt; (category 3)</td>
</tr>
</tbody>
</table>

---

<sup>b</sup>See Principles of Surgery (PN-A).<sup>c</sup>Moh's surgery is an option.<sup>d</sup>Complete excision of the skin with a wide negative margin with skin grafting is needed. STSG = split-thickness skin graft; FTSG = full-thickness skin graft. <sup>e</sup>See Principles of Radiotherapy (PN-B).<sup>f</sup>Recommend intraoperative frozen sections to achieve negative margins.<sup>g</sup>Appropriate with proven negative margins for tumors involving the glans only.<sup>h</sup>When it is necessary to dissect into the corpora cavernosum to achieve a negative margin, a partial or total penectomy is performed.<sup>i</sup>See Principles of Chemotherapy (PN-C).

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**MANAGEMENT OF NON-PALPABLE INGUINAL LYMPH NODES**

**NODAL STATUS**  
**RISK STRATIFICATION BASED ON PRIMARY LESION**  
**TREATMENT**

- **Non-palpable inguinal lymph nodes**
  - **Low risk** (Tis, Ta, T1a)
    - Surveillance (*See PN-6*)  
      - or Dynamic sentinel node biopsy (DSNB)\(^k,l\) (category 2B)

- **Intermediate risk** (T1b) or **High risk** (Any T2 or G3 or G4)
  - Inguinal lymph node dissection (ILND)\(^m\) or DSNB\(^l\) (category 2B)

---

\(^j\)Ta verrucous carcinoma is by definition a well-differentiated tumor and would require surveillance alone of inguinal lymph nodes.

\(^k\)DSNB is recommended provided the treating physician has experience with this modality.

\(^l\)If positive lymph nodes are found on DSNB, ILND is recommended.

\(^m\)A modified/superficial inguinal dissection with intraoperative frozen section is an acceptable alternative to stage the inguinal lymph nodes.

---

**Note:** All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2014
Penile Cancer

MANAGEMENT OF PALPABLE INGUINAL LYMPH NODES

NODAL STATUS

RISK STRATIFICATION BASED ON PHYSICAL EXAMINATION FINDINGS

TREATMENT

Low-risk primary lesion

Fine-needle aspiration (FNA)

Negative

Excisional biopsy or Surveillance

Positive

ILND

Unilateral lymph node <4 cm

High-risk primary lesion

ILND

≥4 cm lymph node (fixed or mobile)

Management of Bulky/Unresectable Inguinal Lymph Nodes (PN-5)

Palpable inguinal lymph nodes

≥4 cm lymph node (fixed or mobile)

Management of Bulky/Unresectable Inguinal Lymph Nodes (PN-5)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

n Imaging to assess regional nodes and distant metastases.

o High-risk primary lesion: T1, high-grade, LVI, >50% poorly undifferentiated.
MANAGEMENT OF BULKY/UNRESECTABLE INGUINAL LYMPH NODES

NODE STATUS | LYMPH NODES | TREATMENT
---|---|---
Unilateral; mobile | Positive → FNA | Neoadjuvant chemotherapy followed by ILND
Negative | Excisional biopsy
Multiple or bilateral inguinal lymph nodes; mobile or fixed | Positive → FNA | Neoadjuvant chemotherapy
Negative | Neoadjuvant chemotherapy → ILND and PLND
Palpable inguinal lymph nodes ≥4 cm (fixed or mobile) | Pelvic lymph nodes enlarged | Potentially resectable → Neoadjuvant chemotherapy
Non-surgical candidate | Radiotherapy with concurrent chemotherapy | See Surveillance (PN-6)

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
# NCCN Guidelines Version 1.2014
## Penile Cancer

### Surveillance

<table>
<thead>
<tr>
<th>Anatomic Site</th>
<th>Initial Treatment</th>
<th>Surveillance</th>
</tr>
</thead>
</table>
| Primary lesion | • Topical therapy  
• Laser therapy  
• Radiation therapy  
• Wide local excision including circumcision  
• Partial penectomy  
• Total penectomy | Clinical exam:υ,ω  
year 1-2, every 3 mo then  
year 3-5, every 6 mo then  
year 5-10, every 12 mo |
| Lymph nodes | N0, N1 | Clinical exam:υ,ω  
year 1-2, every 6 mo then  
year 3-5, every 12 mo |
| | N2, N3 | Clinical exam:υ  
year 1-2, every 3-6 mo then  
year 3-5, every 6-12 mo  
Imaging:  
• Chest (CT or x-ray)  
  ➢ year 1-2, every 6 mo  
• Abdominopelvic (CT or MRI)  
  ➢ year 1, every 3 mo then  
  ➢ year 2, every 6 mo |

υ Patients on active surveillance of clinically negative nodes and at low risk for inguinal metastases.  
ω Clinical exam includes examination of the penis and inguinal region.  
If an abnormal clinical exam, obese patient, or prior inguinal surgery, then ultrasound, CT, or MRI of the inguinal region can be considered.

**Note:** All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

For patients with recurrence at either local or distant sites, see Management of Recurrent Disease (PN-7).
MANAGEMENT OF RECURRENT DISEASE

Recurrence of penile lesion after initial treatment → Invasion of corpora cavernosa

- Absent → Partial penectomy or Total penectomy or Repeat penile-sparing treatment (category 2B)
- Present → Partial penectomy or Total penectomy

Local recurrence in inguinal region → Consider systemic chemotherapy and/or Consider external beam radiation therapy (EBRT) and/or Consider surgical resection

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
MANAGEMENT OF METASTATIC DISEASE

Metastatic penile cancer →

Systemic chemotherapy\(^i\) or Radiotherapy\(^e\) or Radiotherapy\(^e\) with concurrent chemotherapy\(^i\) → Complete/partial response or stable → Consolidation surgery\(^t\) → See Surveillance (PN-6)

No response/Disease progression → Consider salvage systemic chemotherapy\(^i\) or Consider radiotherapy for local control\(^e\) and/or Best supportive care/clinical trial (See NCCN Guidelines for Palliative Care)

Notes:
- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

\(^i\)See Principles of Chemotherapy (PN-C).
\(^e\)See Principles of Radiotherapy (PN-B).
\(^t\)Consolidation surgery consists of bilateral superficial and deep ILND and possible bilateral PLND.
PRINCIPLES OF SURGERY\(^1\)

- Tis, Ta penile cancer lesions may be amenable to conservative penile organ-sparing approaches, including: topical therapy, local excision, circumcision, laser therapy (category 2B), or glansectomy (category 2B).

- Partial penectomy should be considered the standard for high-grade primary penile tumors, provided a functional penile stump can be preserved and negative margins are obtained.

- Standard or modified ILND or DSNB (category 2B) is indicated in patients with penile cancer in the absence of palpable inguinal adenopathy if high-risk features for nodal metastasis are seen in the primary penile tumor:
  - Lymphovascular invasion
  - \( \geq pT1G3 \) or \( \geq T2 \), any grade
  - \( >50\% \) poorly differentiated

- PLND should be considered at the time of ILND in patients with \( \geq 2 \) inguinal nodes (on frozen section) on the ipsilateral ILND site or in a delayed procedure in patients with extranodal extension.

---

1See Discussion for further details regarding ILND and PLND.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIOTHERAPY

Primary Radiation Therapy (category 2B) (Penile Preservation)

T1-2, N0

If tumor <4 cm
- Circumcision followed by either:
  - Brachytherapy alone (preferred approach)\(^1,2\) (should be performed with interstitial implant);
  - or
  - EBRT with or without chemotherapy:\(^3\) Total dose 65-70 Gy with conventional fractionation using appropriate bolus to primary penile lesion with 2 cm margins.

If tumor ≥4 cm
- Circumcision followed by either:
  - EBRT with chemotherapy:\(^3\) 45-50.4 Gy to a portion of or whole penile shaft depending upon bulk and extent of lesion plus pelvis/inguinal nodes, then boost primary lesion with 2 cm margins EBRT (total dose 60-70 Gy);
  - or
  - Brachytherapy (in select cases and with careful post-treatment surveillance)

T3-4 or N+ (surgically unresectable)

- Circumcision followed by:
  - EBRT with chemotherapy:\(^3\) 45-50.4 Gy to whole penile shaft, pelvic lymph nodes, and bilateral inguinal lymph nodes, then boost primary lesion with 2 cm margins and gross lymph nodes (total dose 60-70 Gy).

Postoperative Adjuvant Radiotherapy

- Inguinal Lymph Node Positive (category 2B)
  - Inguinal and pelvic lymph node EBRT to 45-50.4 Gy (strongly consider concomitant chemotherapy\(^3\)).
  - Boost gross nodes and areas of extracapsular extension to a total dose of 60-70 Gy.
  - Treat primary site of disease if positive margin.

- Primary Site Margin Positive
  - Primary site of disease and surgical scar EBRT to 60-70 Gy (for close margin consider radiation treatment vs. observation).
  - Treat bilateral inguinal lymph nodes and pelvic lymph nodes if no or inadequate lymph node dissection.
  - Brachytherapy (in select cases)

\(^3\)For potential radiosensitizing agents and combinations, see Principles of Chemotherapy (PN-C 2 of 2).
Neoadjuvant

- Neoadjuvant, cisplatin-based chemotherapy should be considered the standard (prior to ILND) in patients with ≥4 cm inguinal lymph nodes (fixed or mobile), if FNA is positive for metastatic penile cancer.¹
  - Patients with initially unresectable (T4) primary tumors may be downstaged by response to chemotherapy.

- A Tx, N2-3, M0 penile cancer can receive 4 courses of neoadjuvant paclitaxel, ifosfamide, and cisplatin (TIP).² Stable or responding patients should then undergo consolidative surgery with curative intent.
  - The phase II response rate was 50% in the neoadjuvant setting.
  - The estimated rate of long-term progression-free survival for intent to treat was 36.7%.
  - Improved progression-free and overall survival times were associated with objective response to chemotherapy.

Adjuvant

- There are no sufficient data to form conclusions about the use of adjuvant chemotherapy. By extrapolation from the neoadjuvant data, it is reasonable to give 4 courses of TIP in the adjuvant setting if it was not given preoperatively and the pathology shows high-risk features. (See Management of Bulky/Unresectable Inguinal Lymph Nodes, PN-5) For high-risk patients, for whom adjuvant EBRT or chemoradiotherapy can also be considered, include those with any of the following:
  - Pelvic lymph node metastases
  - Extranodal extension
  - Bilateral inguinal lymph nodes involved
  - 4 cm tumor in lymph nodes

Metastatic

- TIP is a reasonable first-line treatment for patients with metastatic penile cancer, including palliative treatment of patients with distant metastases.²

- 5-FU + cisplatin has been used historically for metastatic penile cancer and can be considered as an alternative to TIP.³ It appears to be effective for some patients, although the toxicities may be limiting and require dose reductions.⁴

- Bleomycin-containing regimens are associated with unacceptable toxicity⁵ and are no longer recommended.

- There are no randomized clinical trials due to the rarity of penile cancer in industrialized countries.

Second-line

- No standard second-line systemic therapy exists.

- Depending on first-line therapies, palliative options include single-agent therapy such as capecitabine, carboplatin, docetaxel, 5-FU, methotrexate, paclitaxel, and panitumumab.⁴,⁶-¹⁰ Strongly consider a clinical trial.
PRINCIPLES OF CHEMOTHERAPY

Preferred combination chemotherapy regimens

TIP2
Platixal 175 mg/m² IV over 3 hours on Day 1
Ifosfamide 1200 mg/m² IV over 2 hours on Days 1-3
Cisplatin 25 mg/m² IV over 2 hours on Days 1-3
Repeat every 21 days

5-FU + cisplatin4 (category 2B)
Continuous infusion 5-FU 1000 mg/m²/d IV on Days 1-5
Cisplatin 100 mg/m² IV on Day 1
Repeat every 3 to 4 weeks

Radiosensitizing agents and combinations11 (For radiotherapy with concurrent chemotherapy)

• Preferred
  ➢ Cisplatin alone, or in combination with 5-FU
• Alternate options
  ➢ Mitomycin C in combination with 5-FU
  ➢ Capecitabine

References
Table 1

American Joint Committee on Cancer (AJCC)
TNM Staging System for Penile Cancer (7th ed., 2010)

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>ANATOMIC STAGE/PROGNOSTIC GROUPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Stage 0 Tis N0 M0</td>
</tr>
<tr>
<td>T0</td>
<td></td>
</tr>
<tr>
<td>Ta</td>
<td>Stage I T1a N0 M0</td>
</tr>
<tr>
<td>Tis</td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4)</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated</td>
</tr>
<tr>
<td>T2</td>
<td>Tumor invades corpus spongiosum or cavernosum</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor invades urethra</td>
</tr>
<tr>
<td>T4</td>
<td>Tumor invades other adjacent structures</td>
</tr>
</tbody>
</table>

*Note: Broad pushing penetration (invasion) is permitted; destructive invasion is against the diagnosis

<table>
<thead>
<tr>
<th>Regional Lymph Nodes (N)</th>
<th>Clinical Stage Definition*</th>
</tr>
</thead>
<tbody>
<tr>
<td>cNX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>cN0</td>
<td>No lymph node metastasis</td>
</tr>
<tr>
<td>cN1</td>
<td>Palpable mobile unilateral inguinal lymph node</td>
</tr>
<tr>
<td>cN2</td>
<td>Palpable mobile multiple or bilateral inguinal lymph nodes</td>
</tr>
<tr>
<td>cN3</td>
<td>Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral</td>
</tr>
</tbody>
</table>

Pathologic Stage Definition*

| pNX                      | Regional lymph nodes cannot be assessed |
| pN0                      | No regional lymph node metastasis |
| pN1                      | Metastasis in a single inguinal node |
| pN2                      | Metastasis in multiple or bilateral inguinal lymph nodes |
| pN3                      | Extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral |

*Note: Pathologic stage definition based on biopsy or surgical excision.

<table>
<thead>
<tr>
<th>Distant Metastasis (M)</th>
<th>Distant metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>

*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ................................................................. MS-2
Risk Factors ............................................................. MS-2
Clinical Presentation ................................................ MS-2
Characterization and Clinical Staging ....................... MS-2
Management of Primary Lesions ............................. MS-3
Diagnosis ................................................................. MS-3
NCCN Recommendations ......................................... MS-3
Tis or Ta ................................................................. MS-3
T1G1-2 ................................................................. MS-4
T1G3-4 or T≥2 ........................................................ MS-4

Management of Regional Lymph Nodes .................. MS-4
Evaluation and Risk Stratification .......................... MS-4
Dynamic Sentinel Node Biopsy .............................. MS-5
Inguinal Lymph Node Dissection .......................... MS-6
Modified Template Lymphadenectomy .................. MS-6
Delayed Inguinal Lymphadenectomy ...................... MS-7
Unilateral Versus Bilateral Lymphadenectomy .......... MS-7
Pelvic Lymphadenectomy ..................................... MS-7
Chemotherapy ...................................................... MS-8
NCCN Recommendations ..................................... MS-8
Non-Palpable Nodes .............................................. MS-8
Unilateral Palpable Nodes <4 cm .......................... MS-8
Palpable Nodes ≥4 cm (fixed or mobile) ................ MS-8

Surveillance .......................................................... MS-9
Recurrence ........................................................... MS-9
Metastatic Disease ................................................ MS-9
Summary ............................................................. MS-10
References ........................................................... MS-11
Overview

Squamous cell carcinoma (SCC) of the penis is a rare disease, representing 0.4% to 0.6% of all malignant neoplasms among men in the United States and Europe. In 2012, the estimated number of new cases of penile cancer in the United States was 1,570, with 310 predicted cancer-specific deaths. Incidence is higher (up to 10%) among men in the developing countries of Asia, Africa, and South America. The most common age of presentation is between ages 50 and 70. Early diagnosis is of utmost importance, as this is a disease that can result in devastating disfigurement and has a 5-year survival rate of approximately 50% (over 85% for patients with negative lymph nodes and 29%—40% for patients with positive nodes, with the lowest survival rates at 0% for patients with pelvic lymph node [PLN] involvement). As the rarity of this disease makes it difficult to perform prospective, randomized trials, the NCCN Panel relied on the experience of penile cancer experts to minimize the controversies associated with treating penile SCC and collectively lay down a foundation to help standardize the management of the malignancy.

Risk Factors

In the United States the median age of diagnosis is 68 years, with an increase in risk for males older than 50 years. Early detection is assisted by the ability to do a good physical exam. Phimosis may hinder the capability to properly inspect the areas of highest incidence—the glans, inner preputial layer, coronal sulcus, and shaft. Men with phimosis carry an increased risk of 25% to 60%. A more recent review of penile SCC in the United States showed that 34.5% of patients had the primary lesion on the glans, 13.2% on the prepuce, and 5.3% in the shaft, with 4.5% overlapping and 42.5% unspecified. Other risk factors include balanitis, chronic inflammation, penile trauma, tobacco use, lichen sclerosus, poor hygiene, and a history of sexually transmitted disease(s), especially HIV and HPV. Overall, about 45% to 80% of penile cancers are related to HPV, with a strong correlation with types 16 and 18. There is an 8-fold increased risk for patients with HIV, which may correspond to a higher incidence in HPV among males with HIV. Cigarette smokers are noted to be 3 to 4.5 times more likely to develop penile cancer. Patients with lichen sclerosus are noted to have a 2% to 9% risk of developing penile carcinoma. Psoriasis patients undergoing psoralen plus ultraviolet A (PUVA) treatment have an increased incidence of 286 times compared to the general population. Therefore, they should be shielded during treatment and any penile lesion should be closely monitored.

Clinical Presentation

Most often penile SCC presents as a palpable, visible lesion on the penis, which may be associated with penile pain, discharge, bleeding, or a foul odor if the patient delays seeking medical treatment. The lesion may be characterized as nodular, ulcerative, or fungating, and may be obscured by phimosis. The patient may exhibit signs of more advanced disease, including palpable nodes and/or constitutional symptoms (eg, fatigue, weight loss).

Characterization and Clinical Staging

SCC is the most common variant of penile cancer. Penile intraepithelial neoplasia (PIN) is a premalignant condition at high risk of developing into SCC of the penis. The AJCC recognizes four subtypes of SCC: verrucous, papillary squamous, warty, and basaloid. The verrucous subtype is felt to be of low malignant potential, while other variants reported—adenosquamous and sarcomatoid variants—carry a worse prognosis. The primary lesion is further characterized by its growth pattern with superficial spread, nodular or vertical-phase growth, and verrucous pattern. In addition to the penile lesion, evaluation of lymph
nodes is also critical, as involvement of the inguinal lymph nodes (ILNs), the number and site of positive nodes, and extracapsular nodal involvement provide the strongest prognostic factors of survival.\(^4,20\)

The AJCC Tumor, Nodes, and Metastasis (TNM) system for penile carcinoma has been used for staging, with the most recent update published in 2010. It was initially introduced in 1968 and was subsequently revised in 1978, 1987, and 2002.\(^17,21-24\) In the 2010 update, the AJCC has made the distinction between clinical and pathologic staging while eliminating the difference between superficial and deep inguinal metastatic nodes.\(^17\) Other changes to the 2010 TNM system include: T1 subdivided into T1a and T1b determined by the presence or absence of lymphovascular invasion or poorly differentiated cancers; the T3 category is now limited to urethral invasion and T4 is limited to prostatic invasion; and stage II grouping includes T1b N0M0 as well as T2-3 N0M0 (see staging tables in the algorithm). A grading system for SCC of the penis based on degree of cell anaplasia is defined as: grade 1, well differentiated (no evidence of anaplasia); grade 2, moderately differentiated (<50% anaplasia); and grade 3, poorly differentiated (>50% anaplastic cells).\(^25\) According to the AJCC, if no grading system is specified, a general system should be followed: GX, grade cannot be assessed; G1-3 as previously mentioned above; and G4, undifferentiated.\(^17\) The overall degree of cellular differentiation with high-risk, poorly differentiated tumors is an important predictive factor for metastatic nodal involvement.\(^26\) The AJCC also recommends collection of site-specific factors, including: the distinction between corpus spongiosum and corpus cavernosum involvement, the percentage of tumor that is poorly differentiated, the depth of invasion in verrucous carcinoma, the size of the largest lymph node metastasis, and HPV status.\(^17\)

### Management of Primary Lesions

#### Diagnosis

Evaluation of the primary lesion, regional lymph nodes, and distant metastasis will dictate the appropriate and adequate management of SCC of the penis, beginning with the first evaluation at presentation and then throughout follow-up. Vital to the initial management is a good physical exam of the penile lesion(s) that remarks on the diameter of the lesion(s) or suspicious areas; location(s) on the penis; number of lesions; morphology of the lesion(s); whether the lesion(s) are papillary, nodular, ulcerous, or flat; and relationship with other structures including submucosal, urethra, corpora spongiosa, and/or corpora cavernosa. To complete the initial evaluation, histologic diagnosis with a punch, excisional, or incisional biopsy is paramount in determining the treatment algorithm based on a pathologic diagnosis.\(^17,27\) This will provide information on the grade of the tumor, and will assist in the risk stratification of the patient for regional lymph node involvement.\(^27\) MRI or ultrasound can be used to evaluate the depth of tumor invasion.\(^28\) For the evaluation of lymph nodes, see Management of Regional Lymph Nodes.

#### NCCN Recommendations

**Tis or Ta**

For patients with penile carcinoma *in situ* or noninvasive verrucous carcinoma, penis-preserving techniques may be utilized, including topical imiquimod (5%) or 5-FU cream, circumcision and wide local excision such as Mohs surgery, laser therapy (category 2B) using carbon dioxide or neodymium:yttrium-aluminum-garnet, and complete glansectomy (category 2B). Among these, topical therapy\(^29-31\) and excisional organ-sparing surgery\(^32\) are the most widely used. Retrospective studies of laser therapy reported local recurrence rates of
around 18% comparable to that of surgery, with good cosmetic and functional results.33,34 Glansectomy, removal of the glans penis, has also been studied with no recurrence observed in some cases.35-38

T1G1-2
Careful consideration should be given to penile-preserving techniques if the patient is reliable with regards to compliance with close follow-up. These techniques include wide local excision as well as Mohs surgery as an option plus reconstructive surgery,39 laser therapy (category 2B),40 and radiotherapy delivered as external beam radiation therapy (EBRT) or brachytherapy with interstitial implant (category 2B).41-45 Emphasis is placed again on patient selection and close follow-up, as the 2-year recurrence rate may reach up to 50%.46 Recent studies have shown that surgical margins of 5 to 10 mm are as safe as 2-cm surgical margins, and 10- to 20-mm margins provide adequate tumor control.47 Circumcision should always precede radiation therapy (RT) to prevent radiation-related complications.

T1G3-4 or T2
These lesions typically require more extensive surgical intervention with partial or total penectomy depending on the characteristics of the tumor and depth of invasion.27 Intraoperative frozen sectioning is recommended to achieve negative surgical margins. If the tumor encompasses less than half of the glans and the patient agrees to very close observation, then a more conservative approach such as wide local excision or glansectomy may be considered. The patient should understand that there is an increased risk for recurrence and potential for a repeat wide local excision should a local recurrence be noted, provided there is no invasion of the corpora cavernosa.34,38 A clear and frank discussion should be had with the patient that a partial or total penectomy will likely be required should a larger or more invasive lesion be present.

The tumor size is an important factor when choosing RT as treatment. As the average length of the glans is about 4 cm, this serves as a cutpoint to reduce the risk of under-treating cavernosal lesions. In a study of 144 patients with penile cancer restricted to the glans treated by brachytherapy, larger tumors, especially those over 4 cm, are associated with higher risk of recurrence.48 A high, 10-year, cancer-specific survival rate of 92% was achieved in this series.

There was nonuniform consensus among NCCN Panelists on the use of RT as primary therapy due to scant data. RT alone is a category 2B recommendation, while RT with concurrent chemotherapy is a category 3 recommendation. RT should be given after circumcision has been performed.

For tumors smaller than 4 cm, brachytherapy with interstitial implant is preferred, but EBRT with or without chemotherapy is a viable option. Consider prophylactic ILN irradiation if selecting EBRT. For tumors 4 cm or larger, EBRT combined with chemotherapy may be used. Brachytherapy may still be appropriate in select cases, but careful monitoring is necessary as the risks of complications and failures increase.49 Crook and colleagues reported a 10-year cause-specific survival of 84% in 67 patients with T1-2 (select cases of T3) penile lesions treated with primary brachytherapy.45

Post-surgical RT to the primary tumor site may be considered for positive margins.

Management of Regional Lymph Nodes
Evaluation and Risk Stratification
The presence and extent of regional ILN metastases has been determined to be the single most important prognostic indicator in determining long-term survival in men with invasive penile SCC.20
Evaluation of the groin and pelvis is an essential component of the metastatic workup of a patient. The involvement of the ILN can be clinically evident (ie, palpable versus non-palpable), adding to the difficulty in management. Clinical exam for ILN involvement should attempt to evaluate and assess for palpability, number of inguinal masses, unilateral or bilateral, dimensions, mobility or fixation of nodes or masses, relationship to other structures (eg, skin, Cooper’s ligaments), and edema of the penis, scrotum, and/or legs.\(^50,51\) Crossover drainage from left to right and vice versa does occur and is reproducible with lymphoscintigraphy.\(^4,52\) The physical exam should describe the diameter of node(s) or mass(es), unilateral or bilateral localization, number of nodes identified in each inguinal, and the relationship to other structures (eg, skin, Cooper’s ligament), with respect to infiltration, perforation, etc. Imaging for palpable disease by CT or MRI may be used to assess the size, extent, location, and structures that are in close proximity to the ILN, as well as the presence of pelvic and retroperitoneal lymph nodes and distant metastasis. CT and MRI are limited in patients with non-palpable disease.\(^50,53\) While studies have looked at the use of nanoparticle-enhanced MRI, PET/CT, and 18F-fluorodeoxyglucose (FDG) PET/CT, their small sample size requires validation in larger prospective studies.\(^54-57\) When considering one imaging modality to evaluate the stage of the primary lesion and lymph node status, MRI appears to be the best choice to enhance the physical exam in patients where the inguinal region is difficult to assess (eg, morbidity, previous chemo/radiotherapy).\(^54,58\)

Consideration needs to be given to whether or not the primary lesion demonstrated any adverse prognostic factors. If one or more of these high-risk features is present, then pathologic ILN staging must be performed. Up to 25% of patients with non-palpable lymph nodes harbor micrometastases.\(^25\) Therefore, several predictive factors have been evaluated to help predict the presence of occult lymph node metastasis.\(^46,59\) Slaton et al\(^25\) concluded that patients with pathologic stage T2 or greater were at significant risk (42%–80%) of nodal metastases if they exhibited greater than 50% poorly differentiated cancer and/or vascular invasion, and therefore should be recommended to undergo an inguinal lymph node dissection (ILND).\(^4,25\) These factors can then further define patients into low-, intermediate-, and high-risk groups for lymph node metastasis.\(^18,60,61\) The European Association of Urology determined risk stratification groups for patients with non-palpable ILNs, and validated this in both uni- and multivariate analyses of prognostic factors. Patients can be stratified based on stage and/or grade into risk groups based on the likelihood of harboring occult node-positive disease, with the low-risk group defined as those patients with Tis, Ta, or T1a, the intermediate group as those with T1b (lymphovascular invasion), and the high-risk group as those with T2 or G3/G4.\(^51,60\)

**Dynamic Sentinel Node Biopsy**

The work by Cabanas used lymphangiograms and anatomic dissections to evaluate the sentinel lymph node drainage for penile cancer with non-palpable ILNs.\(^62\) This technique has been shown to have false-negative rates as high as 25%; therefore, it is no longer recommended.\(^51,63\) Advancements have been made with the dynamic sentinel node biopsy (DSNB) technique developed for penile cancer by the Netherlands Cancer Institute using lymphoscintigraphy and performed with technetium-99m–labeled nanocolloid and patent blue dye isosulfan blue.\(^64,65\) Initially, this technique was associated with a low sensitivity and high false-negative rate (16%–43%).\(^66-69\) Refinement of the technique to improve the false-negative rate includes serial sectioning and immunohistochemical staining of pathologic specimens, preoperative ultrasonography with and without fine needle aspiration.
(FNA) cytology, and exploration of groins in which no sentinel node is visualized on intraoperative assessment, achieving a decrease in false-negative rate from 19% to only 5%.\textsuperscript{64,70} Using FNA with ultrasound can increase the diagnostic yield in metastasis >2 mm in diameter.\textsuperscript{53,71} Crashaw et al\textsuperscript{72} used ultrasound with DSNB and noted improved accuracy in identifying patients with occult lymph node metastases. With modification of the NCI protocol, Hadway et al\textsuperscript{73} were able to achieve a similar false-negative rate (5%) with an 11-month follow-up. Secondary to the technical challenges associated with DSNB, to be accurately and reliably performed, it is recommended that DSNB be performed at tertiary care referral centers where at least 20 procedures are done per year.\textsuperscript{64,74} It should be noted that DSNB is not recommended in patients with palpable ILNs.\textsuperscript{50}

**Inguinal Lymph Node Dissection**

The most frequent sites of metastasis from penile cancer are the ILNs, typically presenting as palpable inguinal lymphadenopathy. The management of ILNs by ILND has been fraught with great fears of surgical morbidity.\textsuperscript{51,75} Early treatment of lymph node involvement has been shown to have a positive impact on survival, except if the patient has bulky nodal spread or other sites of metastases.\textsuperscript{76,77} Palpable lymphadenopathy at the time of diagnosis does not warrant an immediate ILND. Of the patients with palpable disease, 30% to 50% will be secondary to inflammatory lymph node swelling instead of metastatic disease.\textsuperscript{59} Although the distinction between reactive lymph nodes and metastatic disease has traditionally been done with a 6-week course of antibiotics, FNA is becoming the most favored approach among many penile cancer experts for patients with palpable nodes.\textsuperscript{4,50} In this setting, antibiotics are useful if the patient has a suspected underlying cellulitis at the site of palpable inguinal lymphadenopathy and future site of ILND.\textsuperscript{4,50,78}

The boundaries of the standard, full-template ILND (ie, Daseler’s quadrilateral area) are: superiorly, the inguinal ligament; inferiorly, the fossa ovalis; laterally, the medical border of sartorius muscle; and medially by the lateral edge of adductor longus muscle.\textsuperscript{78} Historically, it has been recommended to keep the patient on bed rest for 48 to 72 hours, especially after myocutaneous flaps or the repair of large skin defects, although the necessity for this is debatable and not corroborated with rigorous scientific data. Closed suction drains are placed at surgery and are typically removed when drainage is less than 50 to 100 mL per day.\textsuperscript{78,79} Consideration should be given to keeping the patient on a suppressive dose of an oral cephalosporin (or other gram positive covering broad spectrum) for several days to weeks postoperatively in an attempt to decrease the risk of wound-related issues and minimize the risk for overall complications. However, the data supporting this treatment approach are very limited.\textsuperscript{78}

**Modified Template Lymphadenectomy**

In attempts to decrease the morbidity associated with standard ILND, a modified template lymphadenectomy has been proposed that uses a shorter skin incision, limiting the field of inguinal dissection by excluding the area lateral to the femoral artery and caudal to the fossa ovalis, with preservation of the saphenous vein and elimination of the need to transpose the sartorius muscle while providing an adequate therapeutic effect. This technique is commonly reserved for patients with a primary tumor that places them at increased risk for inguinal metastasis but with clinically negative groins on examination.\textsuperscript{78,80} The modified technique has shown a decrease in complications. Contemporary modified ILND should include the central and superior zones of the inguinal region, as these sections were not included in the dissection leading to a false-negative rate of 15%.\textsuperscript{81,82} It is important to note that if nodal involvement is detected on frozen section, the surgical procedure should be
converted to a standard, full-template lymphadenectomy. A standard full-template lymphadenectomy should be considered in all patients who have resectableinguinal lymphadenopathy. However, recent studies would favor neoadjuvant chemotherapy prior to proceeding with surgery, particularly in patients with bulky ILN metastases (ie, fixed nodes or nodal diameter >3 cm). Generally, ILND is performed within 4 to 6 weeks following the completion of systemic chemotherapy to allow patient recovery while minimizing the risk of cancer progression post-chemotherapy.

**Delayed Inguinal Lymphadenectomy**

Since data exist that suggests that men with clinically negative groins undergoing immediate ILND have better survival outcomes than men undergoing delayed ILND once their groins are clinically positive, in most circumstances men with high-risk penile tumors should undergo immediate ILND. However, patients with lower-risk tumors who are undergoing active surveillance or high-risk men who refuse immediate ILND may experience an inguinal nodal recurrence at some time point during follow-up. The median time to inguinal recurrence after treatment of the primary penile tumor is approximately 6 months, 90% occurring by year 3 and 100% by year 5.

**Unilateral Versus Bilateral Lymphadenectomy**

In patients with high-risk features that do not have palpable lymph nodes, bilateral lymphadenectomy is generally performed. This is because it is not possible to predict the laterality of inguinal nodal metastasis based on the location of the tumor on the penis. Similarly, in patients who have a unilateral palpable node, about 30% will have contralateral positive nodes that were just not palpable. Therefore, bilateral lymphadenectomy should be considered the standard of care in patients undergoing immediate ILND for high-risk penile tumors or because of palpable nodes. When there is a delayed (>1 year after treatment of the primary penile tumor) inguinal recurrence of cancer, it is usually unilateral, and some authors have suggested that ipsilateral ILND is adequate while others have advocated for bilateral ILND in this circumstance.

**Pelvic Lymphadenectomy**

Approximately 20% to 30% of patients with positive ILNs will also have cancer within PLNs. Interestingly, penile tumors do not appear to metastasize to the PLNs without first affecting the inguinal node echelon (ie, no skip lesions). The presence of cancer within the PLN is associated with a very poor 5-year survival rate typically of less than 10%. Based on these prior reports, pelvic lymphadenectomy (resection of external iliac, internal iliac, and obturator lymph nodes) is recommended in patients with 2 or more positive ILNs and in the clinical context of high-grade cancer within the ILN pathologic specimen. Pelvic lymph node dissection (PLND) can be conducted during the same operative session as the ILND if the intraoperative frozen section is positive in 2 or more of the inguinal nodes (raising the importance of obtaining a lymph node count intraoperatively) or in a delayed staged fashion based on the pathologic features of the ILND specimen.

One area of controversy is whether the PLND should be performed ipsilaterally or bilaterally in patients with unilateral positive ILNs. Crossover (right to left or left to right) of inguinal to pelvic nodes has not been well studied and hence both approaches are feasible and left at the discretion of the surgeon based on case-specific characteristics.
Chemotherapy

A patient who presents with resectable bulky disease will rarely be cured with a single treatment modality. Consideration should be given to neoadjuvant chemotherapy if ILNs are ≥ 4 cm. Patients who may benefit from surgical consolidation would be those who had stable, partial, or complete response following systemic chemotherapy, thus increasing their potential for disease-free survival. Recently, Pagliaro et al performed a phase II clinical trial in 30 patients, with stage N2 or N3 (stage III or stage IV) penile cancer without distant metastases, receiving neoadjuvant chemotherapy with paclitaxel, ifosfamide, and cisplatin. In their series, 50% of patients were noted to have a clinically meaningful response and 22 (73.3%) subsequently underwent surgery. There was an improved time to progression and overall survival associated with chemotherapy responsiveness ($P < .001$ and $P = .001$, respectively), absence of bilateral residual tumor ($P = .002$ and $P = .017$, respectively), and absence of extranodal extension ($P = .001$ and $P = .004$, respectively) or skin involvement ($P = .009$ and $P = .012$, respectively).

NCCN Recommendations

**Non-Palpable Nodes**

Most low-risk patients are followed with a surveillance protocol, as the probability of occult micrometastases in ILNs is less than 17%. For patients at high or intermediate risk, a modified or radical inguinal lymphadenectomy is strongly recommended as occult metastatic disease ranges between 68% and 73%. If positive nodes are present on the frozen section, then a superficial and deep inguinal lymphadenectomy should be performed (with consideration of a PLND).

As DSNB is currently not widely practiced in the United States, it is a category 2B option for examining non-palpable nodes to determine the need for a modified lymphadenectomy in place of predictive factors. This technique should be performed in tertiary care referral centers with substantial experience. DSNB is not recommended for Ta tumors as observation alone of the ILNs is sufficient for these well-differentiated lesions in the absence of palpable adenopathy.

**Unilateral Palpable Nodes < 4 cm**

FNA of the lymph nodes is considered standard for these patients if no risk feature is present in the primary lesion. Risk features include T1, high grade, lymphovascular invasion, and poor differentiation in over half of the tumor cells. The NCCN Panel recommends omitting the procedure for patients with high-risk primary lesions to avoid delay of lymphadenectomy. A negative FNA biopsy should be confirmed with an excisional biopsy. Alternatively, careful surveillance may be considered following a negative FNA. Positive findings from either procedure warrant an immediate ILND.

**Palpable Nodes ≥ 4 cm (fixed or mobile)**

Large, unilateral, mobile nodes should first be confirmed by FNA. A negative FNA should be confirmed by an excisional biopsy. Patients with confirmed nodes are amenable to standard or modified ILND. Neoadjuvant chemotherapy should be considered before surgery. No further treatment is necessary if no viable tumor elements are detected in the surgical specimen. Patients with viable disease in a single node after undergoing systemic chemotherapy can be considered for a PLND. Category 2B is assigned to adjuvant chemotherapy. PLND with or without postoperative radiation is also a category 2B recommendation.

In the case of multiple or bilateral ILNs, patients should undergo an FNA of the lymph nodes regardless of whether these are mobile or fixed. A negative result should be confirmed with excisional biopsy. If results are
again negative, the patient should be closely followed. Patients with a positive aspiration or biopsy should receive neoadjuvant chemotherapy followed by ILND and PLND.

Patients with abnormal PLNs on imaging (CT or MRI) are stratified by resectability. Nonsurgical candidates should be treated by chemoradiation. Patients with resectable disease should receive neoadjuvant systemic chemotherapy with consideration of a confirmatory percutaneous biopsy or PET/CT. Those who respond to therapy or become stable should undergo bilateral superficial and deep ILND and bilateral PLND if possible. Those who progress may receive additional systemic chemotherapy with consideration of local-field radiation or participation in a clinical trial.

**Surveillance**

Initial treatment of the primary tumor and lymph nodes dictates the follow-up schedule (see algorithm). A large retrospective review of 700 patients found that penile-sparing therapies carry a significantly higher risk of local recurrence (28%) than partial or total penectomy (5%) and thus require closer surveillance. Patients without nodal involvement had a regional recurrence rate of 2% compared to 19% for patients with N+ disease. Of all recurrences, 92% were detected within 5 years of primary treatment.

Follow-up for all patients includes a clinical exam of the penis and inguinal region. Imaging is not routinely indicated for early disease (except for obese patients or patients who have undergone inguinal surgery since physical exam may be challenging), but may be used upon abnormal findings. For patients with N2 or N3 disease, imaging of the chest, abdomen, and pelvic area is recommended.

**Recurrence**

Invasion of the corpora cavernosa is an adverse finding after initial organ-sparing treatment that warrants partial or total penectomy. For primary tumor recurrences without corpora cavernosa infiltration, salvage penile-sparing options can be considered (category 2B).

A recurrence in the inguinal region carries a poor prognosis (median survival <6 months) and optimal management remains elusive. Possible salvage options include systemic chemotherapy, EBRT, surgery, or a combination thereof.

**Metastatic Disease**

Imaging of the abdomen and pelvis should be obtained when metastasis is suspected to evaluate for pelvic and/or retroperitoneal lymph nodes. PLN metastases is an ominous finding, with a 5-year survival rate of 0% to 66% for all cases and 17% to 54% for microscopic invasion only, with the mean 5-year survival being approximately 10%. In patients with ILN metastases, 20% to 30% will have PLN metastases. This can be further characterized such that if 2 to 3 ILNs are involved, there is a 23% probability of PLN involvement. With 3 or more ILNs this probability increases to 56%.

Pettaway et al evaluated the treatment options for stage IV penile cancer—clinical stage N3 (deep inguinal nodes or pelvic nodes) or M1 disease (distant metastases)—including chemotherapy, radiotherapy, and inguinal lymphadenectomy. Cisplatin-based regimens (paclitaxel, ifosfamide, and cisplatin or alternatively 5-FU plus cisplatin) are the most active first-line systemic chemotherapy regimens. The panel did not recommend regimens containing bleomycin because of high toxicity. Those patients with a proven objective response to systemic chemotherapy are amenable to consolidative ILND with curative
potential or palliation. However, surgical consolidation should not be performed on patients who progress during systemic chemotherapy except for local symptomatic control. Preoperative radiotherapy may also be given to patients who have lymph nodes ≥4 cm without skin fixation to improve surgical resectability and decrease local recurrence. For patients with unresectable inguinal or bone metastases, radiotherapy may provide a palliative benefit after chemotherapy. Salvage systemic chemotherapy may also be considered upon disease progression. Possible choices of monotherapy include capecitabine, carboplatin, docetaxel, 5-FU, methotrexate, paclitaxel, and panitumumab.\(^{103-108}\) However, as consensus is lacking in the second-line setting, the NCCN Panel strongly recommends consideration of clinical trial participation. Best supportive care remains an option for such advanced cases.

**Summary**

SCC of the penis is a disease that mandates prompt medical/surgical intervention and patient compliance to obtain the most favorable outcomes. A thorough history and physical is the initial step in this process, followed by a biopsy of the primary lesion to establish a pathologic diagnosis. Accurate clinical staging allows for a comprehensive treatment approach to be devised, thus optimizing therapeutic efficacy and minimizing treatment-related morbidity. Prognostic factors help predict if lymph node metastases are suspect in the absence of any palpable inguinal lymphadenopathy. When clinically indicated, an ILND has curative potential, particularly when performed early, with contemporary surgical series demonstrating its reduced morbidity.
References


